Acorda files for bankruptcy, reveals asset sale plan
Bio Pharma Dive
APRIL 2, 2024
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
Tue.Apr 02, 2024
306 
IPC’s Pharmacovigilance Programmes complements CDSCO & Pharmexcil initiatives to fortify patient safety
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 2, 2024
In a concerted effort to bolster patient safety measures within the healthcare landscape, the Indian Pharmacopoeia Commission (IPC) is set to roll out its Skill Development Programmes on Pharmacovigilance.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Ginkgo, in search of more cell therapy tools, buys another startup
Bio Pharma Dive
APRIL 2, 2024
An acquisition of Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.
The Hidden Cause of Alzheimer’s May Have Been Identified a Century Ago
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 2, 2024
Alzheimer’s disease is commonly associated with clumps and tangles of proteins building up in brain cells. Yet for more than a century, accumulations of a completely different material have also been linked with the neurodegenerative condition.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Verve pauses base editing study after treatment side effect
Bio Pharma Dive
APRIL 2, 2024
Lab test abnormalities in one study participant led the company to halt enrollment and prioritize a different version of its gene editing therapy for heart disease.
ICR collaboration forms national NHS patient database registry for Lynch syndrome patients
Pharma Times
APRIL 2, 2024
The genetic condition affects one in 279 people in England and significantly increases cancer risk
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Merz makes a $185m bid for assets from bankrupt Acorda
Pharmaceutical Technology
APRIL 2, 2024
Merz placed a “stalking horse bid” for Acorda’s Parkinson’s disease and multiple sclerosis treatments.
Roivant reveals positive immune drug data, share buyback plans
Bio Pharma Dive
APRIL 2, 2024
A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.
FDA settles ivermectin lawsuit, removes contentious COVID-19 posts
BioPharma Reporter
APRIL 2, 2024
The FDA has agreed to permanently remove several social media posts urging people not to take ivermectin for the treatment of COVID-19, after a lawsuit brought by three doctors accused the regulatory body of interfering with their ability to practice medicine.
A dementia-focused VC digs past amyloid for new kinds of brain drugs
Bio Pharma Dive
APRIL 2, 2024
The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.
Researchers reveal people with Parkinson’s more likely to experience delirium in hospital
Pharma Times
APRIL 2, 2024
Two out of three people with the neurodegenerative condition experienced delirium in hospital
Xilio fires 21% of its workforce and reprioritises pipeline
Pharmaceutical Technology
APRIL 2, 2024
Xilio will focus its resources on clinical development plans for two Phase I candidates, including an asset licenced to Gilead.
Eli Lilly's popular diabetes drug Mounjaro to face continued supply squeeze through April, FDA says
Fierce Pharma
APRIL 2, 2024
Amid steadily increasing demand for Eli Lilly’s popular diabetes med Mounjaro, it appears patients on multiple dose strengths may have to wait even longer than anticipated to re-up on supply. | Four dose strengths are now expected to be in short supply through April, according to the FDA. The agency previously expected the squeeze to let up at the end of March.
Overcoming the added patient burden in DCTs
Pharmaceutical Technology
APRIL 2, 2024
Using the right translation and accessibility tools can facilitate patient comprehension and avoid costly delays in DCTs.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Securing the future: Innovating pharmaceutical supply chain for resilience and safety
pharmaphorum
APRIL 2, 2024
Explore the innovative use of artificial intelligence (AI) and machine learning (ML) in securing the pharmaceutical supply chain for resilience and safety. Learn how cutting-edge technology is shaping the future of pharmaceutical logistics.
Cellenkos links with Mount Sinai to explore CK0804 for myelofibrosis
Pharmaceutical Technology
APRIL 2, 2024
Cellenkos has signed a sponsored research agreement with the Icahn School of Medicine at Mount Sinai, New York, to investigate CK0804.
Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales
Fierce Pharma
APRIL 2, 2024
After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal | Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug Amprya ahead of a court auction.
Edenbridge selects PANTHERx to distribute Yargesa capsules
Pharmaceutical Technology
APRIL 2, 2024
Edenbridge Pharmaceuticals has selected PANTHERx Rare to distribute Yargesa (miglustat) capsules for the treatment of Type 1 Gaucher disease.
Ending the silence: Why the menopause matters in the workplace
pharmaphorum
APRIL 2, 2024
Discover the importance of addressing menopause in the workplace and the benefits of hormone replacement therapy (HRT) through this insightful and informative article on breaking the stigma.
Magazine: What’s next for AAV gene therapies in 2024?
Pharmaceutical Technology
APRIL 2, 2024
In this issue: High-profile gene therapies that use AAV vectors, new research into HIV-TB coinfection treatments, traceability technologies for the supply chain, and more.
AZ, Daiichi Sankyo file Dato-DXd for second indication
pharmaphorum
APRIL 2, 2024
AstraZeneca and Daiichi Sankyo file for approval of datopotamab deruxtecan (Dato-DXd) for second indication in breast cancer.
Alexion’s Voydeya gains FDA approval for extravascular haemolysis
Pharmaceutical Technology
APRIL 2, 2024
Alexion has received the approval of the US Food and Drug Administration (FDA) for Voydeya as an add-on therapy.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
The future of AI: Machine learning working together with scientific expertise
pharmaphorum
APRIL 2, 2024
In a new episode of the pharmaphorum podcast recorded live on site at WIRED Health in London in March, web editor Nicole Raleigh spoke with Elise de Reus, co-founder of Cradle, the generative AI platform that helps scientists to design and program proteins.
Eisai agrees to divest rights for two therapies to Kaken
Pharmaceutical Technology
APRIL 2, 2024
Eisai to sell rights for two of its long-standing products in Japan, Merislon and Myonal, to Kaken Pharmaceutical.
Teva, Viatris revive patent challenge on J&J's long-acting schizophrenia blockbuster Invega Sustenna
Fierce Pharma
APRIL 2, 2024
After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. | After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia drug.
The Power of Patient Adherence Tools to Improve the Patient Journey
Pharmaceutical Commerce
APRIL 2, 2024
Why manufacturers should leverage technology to address low adherence rates.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Courts clear hurdles for Liquidia's Yutrepia, potentially allowing for new rival to United's PAH franchise
Fierce Pharma
APRIL 2, 2024
The FDA now has clearance to approve Liquidia’s pulmonary arterial hypertension treatment Yutrepia after two favorable court decisions last week.
Acorda filed for bankruptcy, and Merz is eyeing its assets
pharmaphorum
APRIL 2, 2024
Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Merz. The announcement made last night US time sparked a run on Acorda's shares, down almost 62% at the time of writing. The news emerged shortly after Acorda cancelled its fourth-quarter results conference call, which was scheduled to take place yesterday.
Pharma Pulse 4/2/24: Tackling Barriers to Adopting BYOD, Lonely Men with HIV More Likely to Smoke & more
Pharmaceutical Commerce
APRIL 2, 2024
The latest news for pharma industry insiders.
Ipsen licenses Sutro ADC in $900m deal
pharmaphorum
APRIL 2, 2024
Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category. The deal, which has a top-end value of $900 million including $90 million in near-term payments, focuses on STRO-003, a preclinical-stage ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content